HAOs dodge disclosure of pharma donor ties
February 3rd 2011Health advocacy organizations that promote research and access to healthcare services for members routinely fail to disclose their financial ties to the pharmaceutical industry, according to a study released online in the American Journal of Public Health.
Analgesic medication errors are common
February 3rd 2011Medication errors involving analgesics, including mistakes in prescribing, are a major contributor to suboptimal therapeutic outcomes and preventable adverse patient events, according to a study published in The Journal of Pain, reported Newswise.com.
ACIP updates antiviral guidelines for flu treatment
February 3rd 2011The US Centers for Disease Control and Prevention Advisory Committee on Immunization Practices has issued updated guidelines regarding the use of antiviral agents for the treatment and chemoprophylaxis of influenza, according to a report in the January 21 issue of the Morbidity and Mortality Weekly Report. The new recommendations, which include a summary of the effectiveness and safety of antiviral treatment medications, update those issued by the committee in 2008.
Eisai receives CRL for GERD drug
February 2nd 2011FDA has issued a complete response letter to Eisai for its rabeprazole sodium extended-release capsules, 50 mg, an investigational proton pump inhibitor (PPI) under review for the healing and long-term maintenance of healing and symptom resolution of erosive GERD, and for the treatment of daytime and nighttime heartburn and other symptoms of non-erosive GERD.
Half of Americans polled don't think vaccines cause autism
February 1st 2011Half of Americans polled don't think vaccines cause autism. However, 18% are convinced that vaccines, like the MMR vaccine, can cause the disorder, and another 30% aren't sure, according to a new Harris Interactive/HealthDay poll.
Generic competition expected to be strong as many small-molecule drug brands face patent expirations
February 1st 2011Small-molecule drugs in the United States will experience the greatest degree of brand erosion as patents of many of the most popular drugs expire during the next several years, leaving them exposed to generic competition, according to a report published by Datamonitor.
USP wants new Rx label standards
February 1st 2011New draft standards from the U.S. Pharmacopeial Convention could bring dramatic changes to Rx labels as early as 2012. Changes to USP Chapter 17, Prescription Container Labeling, include larger font, placement of the most important information at the top, more understandable language, and more white space.
HHS brief examines factors affecting generic use and cost savings
January 25th 2011With several blockbusters going off patent, Secretary Kathleen Sebelius of the U.S. Department of Health and Human Services asked the office of the Assistant Secretary for Planning and Evaluation to ?examine barriers to and identify opportunities for increasing generic use.?
Study proves that even with increased drug costs, adherence will reduce overall health spending
January 25th 2011A new study conducted by CVS Caremark and published in Health Affairs, found that among patients who had increased drug costs but were adherent with their medications, a ?substantial medical savings as a result of reductions in hospitalization and emergency department use? was realized.
SAMHSA reports 10 years of trends in alcohol- and substance-abuse treatment
January 25th 2011The United States Department of Health and Human Services division of Substance Abuse and Mental Health Services Administration has released a study examining trends of admissions to U.S. substance abuse treatment facilities of people aged 12 years and over, during the period from 1998 to 2008.
FDA approves ready-to-use 750-mg dosage of vancomycin
January 21st 2011FDA has approved the premix formulation of vancomycin injection, USP (750 mg/150 mL) (Baxter). Vancomycin is an antibiotic used to treat severe infections caused by susceptible strains of methicillin-resistant Staphylococcus aureus and/or treat patients who are penicillin-resistant.
FDA sends complete response letter to MannKind regarding new inhaler
January 21st 2011FDA has sent MannKind Corp. a complete response letter regarding the company?s New Drug Application for Afrezza (insulin human [rDNA origin]) Inhalation Powder for the treatment of adult patients with types 1 and 2 diabetes for the control of hyperglycemia.
Merck halts vorapaxar study over bleeding concerns in stroke victims
January 21st 2011Concern that its drug vorapaxar, in trial for its potential to prevent clots, actually increased the risk of bleeding in stroke victims has prompted Merck & Co. to halt a late-stage study of the drug, the Associated Press reported.